Ye Liu - 11 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Reporting relationship: Director
Issuer ticker: EYPT
Reported as of: 11 Jan 2024
Net transaction value: -$37,159,225
SEC form: 4
Accepted by SEC: 16 Jan 2024, 18:01:37 UTC
Prior SEC filing: 07 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Ron Honig, Attorney-in-Fact

Key filing fact

Ye Liu filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 16 Jan 2024.

Key facts

This page summarizes Ye Liu's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Jan 2024, 18:01.

Change

Previous filing in this sequence was filed on 07 Dec 2023.
Current net transaction value: -$37,159,225.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EYPT transaction

Common Stock, $0.001 par value

Sale

Transaction value: $37,159,225
Shares: -1,910,500
Change %: -95%
Price: $19.45
Shares after: 100,221
Date: 11 Jan 2024
Ownership: Ocumension Therapeutics
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.